TrialCancer research communications2022

Safety and Efficacy of Engineered Toxin Body MT-3724 in Relapsed or Refractory B-cell Non-Hodgkin's Lymphomas and Diffuse Large B-cell Lymphoma.

Paul A Hamlin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.